← Back to Clinical Trials
Recruiting NCT05873543

NCT05873543 The Effect of a Smartphone-assisted Hybrid Cardiac Rehabilitation Program in Patients With Heart Failure.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05873543
Status Recruiting
Phase
Sponsor National Taiwan University Hospital
Condition Heart Failure
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2024-01-26
Primary Completion 2028-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
smartphone-assisted hybrid cardiac rehabilitation (SHCR)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2024-01-26 with a primary completion date of 2028-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions: 1. Is the novel cardiac rehabilitation model feasible for patients with HF? 2. Does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?

Eligibility Criteria

Inclusion Criteria: * Patients with heart failure between the ages of 18 and 80 years old. * NYHA (New York Heart Association) functional classification of 1 to 3. * Patients must be in a stable condition and under outpatient follow-up. Exclusion Criteria: * Patients who have contraindications for exercise according to the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription. * Patients who are unable to complete cardiopulmonary exercise testing. * Patients who are unable to follow verbal instructions. * Patients who are unable to walk independently or pedal a stationary bicycle. * Patients who are unable to use communication app on a smartphone. * Patients who already engage in physical activity exceeding the recommended moderate intensity of 150 minutes per week or are currently participating in cardiac rehabilitation. * Patients who do not provide consent to participate in the trial.

Contact & Investigator

Central Contact

Hung-Jui Chuang, MD

✉ rexintwo@gmail.com

📞 00886-2-23123456

Principal Investigator

Hung-Jui Chuang, MD

PRINCIPAL INVESTIGATOR

Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital

Frequently Asked Questions

Who can join the NCT05873543 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05873543 currently recruiting?

Yes, NCT05873543 is actively recruiting participants. Contact the research team at rexintwo@gmail.com for enrollment information.

Where is the NCT05873543 trial being conducted?

This trial is being conducted at Taipei, Taiwan.

Who is sponsoring the NCT05873543 clinical trial?

NCT05873543 is sponsored by National Taiwan University Hospital. The principal investigator is Hung-Jui Chuang, MD at Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology